Docetaxel, Carboplatin, and Pegfilgrastim in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Diagnosis of breast cancer
• * Clinical stage II or III disease (including T2-4, N0-3)
• No clinical or radiological evidence of distant metastases
• * Isolated supraclavicular lymph node involvement allowed
• PATIENT CHARACTERISTICS:
• Age
• 18 and over
• Sex
• Male or female
• Menopausal status
• Not specified
• Performance status
• ECOG 0-1
• Life expectancy
• At least 3 months
• Hematopoietic
• Absolute neutrophil count ≥ 1,500/mm\^3
• Platelet count ≥ 100,000/mm\^3
• Hemoglobin ≥ 10.0 g/dL
• Hepatic
• Bilirubin normal
• Meets 1 of the following criteria:
• * AST or ALT ≤ 5 times upper limit of normal (ULN) AND alkaline phosphatase normal
• * AST or ALT ≤ 1.5 times ULN AND alkaline phosphatase ≤ 2.5 times ULN
• * AST or ALT normal AND alkaline phosphatase ≤ 5 times ULN
• Renal
• Creatinine clearance ≥ 30 mL/min
• Other
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 30 days after study treatment
• No active unresolved infection
• No history of severe hypersensitivity reaction to docetaxel, carboplatin, or any other drug formulated with polysorbate 80
• No known hypersensitivity to E. coli-derived proteins, filgrastim (G-CSF), or pegfilgrastim
• No peripheral neuropathy ≥ grade 2
• No other invasive malignancy within the past 5 years except curatively treated basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
• PRIOR CONCURRENT THERAPY:
• Surgery
• No prior surgical resection for invasive breast cancer
• Other
• No other prior therapy for invasive breast cancer